Compile Data Set for Download or QSAR
Report error Found 172 Enz. Inhib. hit(s) with all data for entry = 9351
TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458963((4-{[2-(4-Bromophenyl)imidazo[,2-a]pyridin-3-yl]me...)
Affinity DataIC50: 1.04nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458968(US10759794, Example 47)
Affinity DataIC50: 2.30nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458964((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 2.80nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459034(US10759794, Example 72)
Affinity DataIC50: 3nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458965((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 4.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458969(US10759794, Example 54)
Affinity DataIC50: 4.30nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458968(US10759794, Example 47)
Affinity DataIC50: 4.90nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459030((4-{[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]...)
Affinity DataIC50: 5.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458967(US10759794, Example 39)
Affinity DataIC50: 6.20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458963((4-{[2-(4-Bromophenyl)imidazo[,2-a]pyridin-3-yl]me...)
Affinity DataIC50: 7.90nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459036(US10759794, Example 74)
Affinity DataIC50: 9.10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459029((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 9.40nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458966((4-{[2-(4-Bromophenyl)imidazo [1,2-a]pyridin-3-yl]...)
Affinity DataIC50: 9.70nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459008(US10759794, Example 43)
Affinity DataIC50: 10nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459031((4-{[2-(4-Cyclopropylphenyl)imidazo[1,2-a]pyridin-...)
Affinity DataIC50: 11nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459007(US10759794, Example 42)
Affinity DataIC50: 13nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458967(US10759794, Example 39)
Affinity DataIC50: 13.4nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458993(US10759794, Example 28)
Affinity DataIC50: 14nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458966((4-{[2-(4-Bromophenyl)imidazo [1,2-a]pyridin-3-yl]...)
Affinity DataIC50: 15nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459033(US10759794, Example 71)
Affinity DataIC50: 16nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458963((4-{[2-(4-Bromophenyl)imidazo[,2-a]pyridin-3-yl]me...)
Affinity DataIC50: 17nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459009(US10759794, Example 44)
Affinity DataIC50: 17nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459035(US10759794, Example 73)
Affinity DataIC50: 17nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458968(US10759794, Example 47)
Affinity DataIC50: 18nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458964((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 20nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458964((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 21.8nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458965((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 27.9nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458965((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 28nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459004(US10759794, Example 38)
Affinity DataIC50: 30nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458969(US10759794, Example 54)
Affinity DataIC50: 38.2nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459029((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 42nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458970(US10759794, Example 55)
Affinity DataIC50: 45nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458966((4-{[2-(4-Bromophenyl)imidazo [1,2-a]pyridin-3-yl]...)
Affinity DataIC50: 46nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458985(US10759794, Example 20)
Affinity DataIC50: 52nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458967(US10759794, Example 39)
Affinity DataIC50: 56nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459003(US10759794, Example 37)
Affinity DataIC50: 60nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458964((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 63nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459000(US10759794, Example 34)
Affinity DataIC50: 63nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459010(US10759794, Example 45)
Affinity DataIC50: 63nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459031((4-{[2-(4-Cyclopropylphenyl)imidazo[1,2-a]pyridin-...)
Affinity DataIC50: 66nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459036(US10759794, Example 74)
Affinity DataIC50: 67nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458977(US10759794, Example 12)
Affinity DataIC50: 71nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459034(US10759794, Example 72)
Affinity DataIC50: 71nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458963((4-{[2-(4-Bromophenyl)imidazo[,2-a]pyridin-3-yl]me...)
Affinity DataIC50: 77nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458970(US10759794, Example 55)
Affinity DataIC50: 79.6nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 3(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM459030((4-{[2-(4-Chlorophenyl)imidazo[1,2-a]pyridin-3-yl]...)
Affinity DataIC50: 93nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458973((4-{[2-(4-Chlorophenyl)imidazo [1,2-a]pyridin-3-yl...)
Affinity DataIC50: 98nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458994(US10759794, Example 29)
Affinity DataIC50: 99nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458981(US10759794, Example 16)
Affinity DataIC50: 110nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetPotassium channel subfamily K member 9(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM458983(US10759794, Example 18)
Affinity DataIC50: 120nMAssay Description:The investigations on the inhibition of the recombinant TASK-1 and TASK-3 channels were carried out using stably transfected CHO cells. Here, the com...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 172 total ) | Next | Last >>
Jump to: